<?xml version="1.0"?>
<case>
<name>Smithkline Beecham Biologicals (S.A.) v Novartis Vaccines and Diagnostics Inc [2007] FCA 1837 (23 November 2007)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2007/1837.html</AustLII>
<citations>
<citation "id=c0">
<class>cited</class>
<tocase>Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513</tocase>
<text>2 After the Commissioner's decision the applicant successfully obtained an amendment. The amendment had the effect of narrowing the claims. Counsel for the respondent accepts that the appeal should proceed to deal with the patent in its amended form. See Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513 at 515, which was accepted as correct, although distinguished on the facts in Airsense Technology Ltd v Vision Systems Ltd (2007) 73 IPR 65 at [13].</text>
</citation>
<citation "id=c1">
<class>cited</class>
<tocase>Airsense Technology Ltd v Vision Systems Ltd (2007) 73 IPR 65</tocase>
<text>2 After the Commissioner's decision the applicant successfully obtained an amendment. The amendment had the effect of narrowing the claims. Counsel for the respondent accepts that the appeal should proceed to deal with the patent in its amended form. See Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513 at 515, which was accepted as correct, although distinguished on the facts in Airsense Technology Ltd v Vision Systems Ltd (2007) 73 IPR 65 at [13].</text>
</citation>
</citations>
</case>